Oncology Molecular Diagnostics Market size is valued at USD 3.63 billion in 2021 and expected to reach a value of USD 8.32 billion by 2028, growing at a CAGR of 12.6% during the forecast period 2022-28 . The global market provides a detailed overview of the Oncology Molecular Diagnostics market and that can be segmented by type, product, test location, and technology. By type, The Oncology Molecular Diagnostics market has been segmented into Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, Kidney Cancer, and Others. The Brest cancer segment is likely to be the largest and fastest-growing segment in terms of type. Based on product the Oncology Molecular Diagnostics Market is segmented into Instruments, Reagents, and Others. Among these, the reagents segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on the test location, the Oncology Molecular Diagnostics Market is segmented into Clinics and Other Establishments, Others. The clinic segment accounts for the largest share in 2021.
In February 2020, Danaher (Cepheid) announced a collaboration with Sherlock Biosciences to explore the innovative, ground-breaking molecular diagnostic test development intended for oncology and infectious diseases deploying CRISPR technology.